Ahead of the Curve: Pharm Exec Profiles Five Recent Drug Launches

Feature

Article

September 11, 2023

Pharmaceutical Executive

Pharmaceutical Executive: September 2023

Volume43

Issue 9

Ahead of the Curve: Pharm Exec Profiles Five Recent Drug Launches

Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.

Follow the links below to read about each product:

Camzyos (Bristol Myers Squibb)

Enhertu (Daiichi Sankyo, AstraZeneca)

Rebyota (Ferring Pharmaceuticals)

Sunlenca (Gilead Sciences)

Tzield (Provention Bio, a Sanofi company)

Selections were made by Pharmaceutical Executive's editorial staff, with close input from Editorial Advisory Board members.

Download Issue PDF

Articles in this issue

Pharmaceutical Executive, September 2023 Issue (PDF)

A New Era of Ethical Leadership

Ahead of the Curve: Pharm Exec Profiles Five Recent Drug Launches

Survival Story: Enhertu

Gut Instinct: Rebyota

Delaying Disease Onset: Tzield

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!